When was LipoCure founded?

LipoCure was founded in 2005 and raised its 1st funding round 15 years after it was founded.

Where is LipoCure located?

LipoCure is headquartered in Jerusalem, Israel.

How many employees does LipoCure have?

As of Jul 31, 2026, the latest employee count at LipoCure is 7.

Is LipoCure a funded company?

LipoCure is a funded company, having raised a total of $***** in its 1st and only funding round, a Grant (prize money) round on Apr 01, 2020.

When was the latest funding round of LipoCure?

LipoCure's latest funding was a $***** Grant (prize money) round on Apr 01, 2020, with participation from 1 investor. Its primary sector is Nanotechnology. Globally, the Nanotechnology sector has seen $1.23B in funding in 2026 to date.

Where does LipoCure rank among its competitors?

LipoCure ranks 1924th amongst 3671 active competitors, of which 1231 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of LipoCure?

LipoCure's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

LipoCure - 2026 Company Profile, Team, Funding & Competitors

LipoCure is a funded company based in Jerusalem (Israel), founded in 2005 by Yechezkel Barenholz. It operates as a Developer of liposome-based nano drugs for cancer, autoimmune diseases, sclerosis, and post-operative pain. LipoCure has raised an undisclosed amount in funding. The company has 3671 active competitors, including 1231 funded and 819 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of liposome-based nano drugs for cancer, autoimmune diseases, sclerosis, and post-operative pain. The proprietary platform allows for the remote drug loading into nanoliposomes and enables controlled release of the drugs at the targeted site allowing for enhanced permeability and retention (EPR). The lead candidate LC-400 in human trials for post-operative pain. Its other programs include LC-100 for breast & ovarian cancer, LC-200 for neuritis, sclerosis, RA lupus, and LC-300 for solid tumors.

Website: lipocurerx.com
Email ID: *****@lipocurerx.com

Key Metrics

Founded Year

2005

Location

Jerusalem, Israel

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Apr 01, 2020, $*****

Investors

Europa & 1 more

Ranked

1924^th among 3671 active competitors

Employee Count

7 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3442 more

View LipoCure's full profile

LipoCure has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Apr 01, 2020 for $*****. 1 investor participated in its latest round. LipoCure has 2 institutional investors.

Here is the list of recent funding rounds of LipoCure:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 01, 2020	3658283	Grant (prize money)	6395239	8701955	2638179	8441871

Access funding benchmarks and valuations. Sign up today!

View details of LipoCure's funding rounds and investors

The founders of LipoCure is Yechezkel Barenholz.

Here are the details of LipoCure's key team members:

Yechezkel Barenholz: Founder of LipoCure.

View details of LipoCure's Founder profiles and Board Members

LipoCure's employee count trend

LipoCure has 7 employees as of Jul 26. Here is LipoCure's employee count trend over the years:

Uncover LipoCure's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LipoCure include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of LipoCure, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1924th	LipoCure 2005, Jerusalem (Israel), Funding Raised	Developer of liposome-based nano drugs for cancer, autoimmune diseases, sclerosis, and post-operative pain	-	Europa, Integra Holdings	30/100